Antibody Information
General Information of This Antibody
| Antibody ID | ANI0GKODU |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Lupartumab |
|||||
| Organization | Bayer AG |
|||||
| Indication | Neoplasms |
|||||
| Synonyms |
BAY 1112623
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-lambda2 |
|||||
| Antigen Name | Ly6/PLAUR domain-containing protein 3 (LYPD3) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSYISSSGSTIYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGLWAFDYWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPG Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSYISSSGSTIYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGLWAFDYWGQGTLVTVSS Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG Click to Show/Hide
|
|||||
| Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GFTFSNAW
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
ISSSGSTI
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
AREGLWAFDY
Click to Show/Hide
|
|||||
| Light Chain Sequence |
ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGV
PDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVLGQPKAAPSV TLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAS SYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGV
PDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSK
QSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
SSNIGAGYV
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
DNN
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
AAWDDRLNGPV
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Lupartumab amadotin [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Inclusion requires age ≥18, ECOG 0-1, life expectancy ≥12 weeks, measurable advanced solid tumors (C4.4a+), and adequate organ function. Exclusion covers recent anticancer therapy (<4 weeks), active skin toxicity, psoriasis, unhealed wounds, serious cardiac/liver disease, CNS metastasis (unless stable >3 months), HIV/HBV/HCV, CKD (GFR <50), recent major surgery, pregnancy, or other high-risk conditions affecting compliance.
Click to Show/Hide
|
||||
| Administration Dosage |
Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02134197 | Clinical Status | PHASE1 | ||
| Clinical Description |
An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a
|
||||
| Primary Endpoint |
The study determines the maximum tolerated dose (MTD) of BAY1129980, defined as the highest dose with <20% DLT incidence during Cycle 1 or the maximum administered dose. Safety is assessed via adverse events (AE) monitoring over 2 years.
|
||||
| Other Endpoint |
Key evaluations include baseline C4.4a tumor expression via IHC, RECIST 1.1-assessed tumor response, BAY1129980 plasma concentration (AUC 0-tlast), and antidrug antibody titers over 2 years.
|
||||